StageZero Life Sciences Profit Margin

The latest profit margin for SZLSF is -104.63% as of September 2024. That compares with -600.84% in the prior-year period — up 82.6% year over year. That is below the sector sector average of 13.23%. Investors often review this figure alongside StageZero Life Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, SZLSF's profit margin moved from -600.84% to -104.63% — a 82.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in StageZero Life Sciences's valuation or profitability profile.

Against its sector companies, SZLSF currently prints -104.63% for profit margin, while the sector average sits near 13.23%. That is roughly 891.1% below the sector mean. Large gaps often invite a closer look at StageZero Life Sciences's growth, margins, and balance sheet.

Profit Margin shows how effectively StageZero Life Sciences converts resources into returns. At -104.63%, SZLSF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -600.84% in the prior-year period — up 82.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SZLSF's profit margin (-104.63%), review year-over-year change from -600.84%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.